Review article · 2020 · Open access

Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product

Balendu Shekhar Jha, Mitra Farnoodian, Kapil Bharti

Stem Cells Translational Medicine, 10(2), 198–208 · Published 18 September 2020 · DOI 10.1002/sctm.20-0242

Open PDFView at the publisherCite this paper

In brief

“Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product” is a 2020 review article by Balendu Shekhar Jha and 2 co-authors, published in Stem Cells Translational Medicine. OpenAlex counts 76 citations as of 21 November 2026, which puts it in the top 2% of works published in 2020 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Stem Cells Translational Medicine.

Citations
76
Most cited in
2024 (20)
Field-weighted impact
0.62
References
74
Authors
3

Abstract

Induced pluripotent stem cells (iPSC)-based therapies have been hailed as the future of regenerative medicine because of their potential to provide treatment options for most degenerative diseases. A key promise of iPSC-based therapies is the possibility of an autologous transplant that may engraft better in the longer-term due to its compatibility with the patient's immune system. Despite over a decade of research, clinical translation of autologous iPSC-based therapies has been slow-partly due to a lacking pre-defined regulatory path. Here, we outline regulatory considerations for developing an autologous iPSC-based product and challenges associated with the clinical manufacturing of autologous iPSCs and their derivatives. These challenges include donor tissue source, reprogramming methods, heterogeneity of differentiated cells, controls for the manufacturing process, and preclinical considerations. A robust manufacturing process with appropriate quality controls and well-informed, prospectively designed preclinical studies provide a path toward successful approval of autologous iPSC-based therapies.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Jha, B. S., Farnoodian, M., & Bharti, K. (2020). Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Translational Medicine, 10(2), 198–208. https://doi.org/10.1002/sctm.20-0242

MLA 9

Jha, Balendu Shekhar, et al. “Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.” Stem Cells Translational Medicine, vol. 10, no. 2, 2020, pp. 198–208. https://doi.org/10.1002/sctm.20-0242.

Chicago

Jha, Balendu Shekhar, Mitra Farnoodian, and Kapil Bharti. 2020. “Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.” Stem Cells Translational Medicine 10 (2): 198–208. https://doi.org/10.1002/sctm.20-0242.

Harvard

Jha, B. S., Farnoodian, M. and Bharti, K. (2020) ‘Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product’, Stem Cells Translational Medicine, 10(2), pp. 198–208. doi:10.1002/sctm.20-0242.

IEEE

B. S. Jha, M. Farnoodian, and K. Bharti, “Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product,” Stem Cells Translational Medicine, vol. 10, no. 2, pp. 198–208, 2020, doi: 10.1002/sctm.20-0242.

BibTeX

@article{jha2020regulatory,
  title     = {{Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product}},
  author    = {Jha, Balendu Shekhar and Farnoodian, Mitra and Bharti, Kapil},
  journal   = {Stem Cells Translational Medicine},
  year      = {2020},
  volume    = {10},
  number    = {2},
  pages     = {198--208},
  doi       = {10.1002/sctm.20-0242},
  url       = {https://doi.org/10.1002/sctm.20-0242}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20211010
202288
20231010
20242020
20251010
20261818

Its field-weighted citation impact is 0.62: it has been cited 0.62 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research

  • induced pluripotent stem cells
  • autologous cell therapy
  • regulatory considerations
  • Investigational New Drug application
  • clinical translation
  • cell manufacturing
  • cellular heterogeneity
  • quality control

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Jha, B. S., Farnoodian, M., & Bharti, K. (2020). Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Translational Medicine, 10(2), 198–208. https://doi.org/10.1002/sctm.20-0242

How many times has this paper been cited?

76 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Stem Cells Translational Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Balendu Shekhar Jha, Mitra Farnoodian, Kapil Bharti.

What is the DOI of this paper?

10.1002/sctm.20-0242, permanently at https://doi.org/10.1002/sctm.20-0242. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.